treatments: search

Genome study focuses search for cancer treatments

The quest for personalised cancer treatments has been given a boost by the announcement of a GBP8.5m ($13m) UK-US alliance to find the best treatments for cancers.

Biomedical Optics & Medical Imaging: Tiny treatments promise big results

Fixed and permeabilized HeLa cells were labeled with mouse anti-α-tubulin primary antibody and 20nM Qdot 625 goat anti-mouse IgG. Photo: Invitrogen Corporation.

Survey Documents Popularity of Alternative Treatments

More than one-third of U.S. adults and nearly 12 percent of children use alternatives to traditional medicine, according to a large federal survey released today that documents how entrenched acupuncture, herbal remedies and other once-exotic therapies have become.

"Stem Cell Tourists" Go Abroad for Unproven Treatments

When Robert Ramirez was diagnosed with Parkinson's disease in 2006, his doctor gave him medication, but little hope: "He told me there wasn't much I could do except wait to 'pass to the other side.'"

Viral DNA In Bacterial Genome Could Hold Key To Novel Cystic Fibrosis Treatments

The bacterium Pseudomonas aeruginosa is well known for its environmental versatility, ability to cause infection in humans, and its capacity to resist antibiotics. P. aeruginosa is the most common cause of persistent and fatal lung infections in cystic fibrosis patients. In a study published online in Genome Research, researchers have used genomic techniques to study a particularly virulent strain of P. aeruginosa, uncovering genetic clues to its success that will aid in the design of novel therapeutic strategies.

Viral DNA In Bacterial Genome Could Hold Key To Novel Cystic Fibrosis Treatments

email icon email to a friend printer icon printer friendly write icon view / write opinions rate icon rate article

Viral DNA in bacterial genome could hold key to novel cystic fibrosis treatments

The bacterium Pseudomonas aeruginosa is well known for its environmental versatility, ability to cause infection in humans, and its capacity to resist antibiotics. P. aeruginosa is the most common cause of persistent and fatal lung infections in cystic fibrosis patients. In a study published in Genome Research, researchers have used genomic techniques to study a particularly virulent strain of P. aeruginosa, uncovering genetic clues to its success that will aid in the design of novel therapeutic strategies.

Viral DNA in bacterial genome could hold key to novel cystic fibrosis treatments

December 2, 2008 The bacterium Pseudomonas aeruginosa is well known for its environmental versatility, ability to cause infection in humans, and its capacity to resist antibiotics. P. aeruginosa is the most common cause of persistent and fatal lung infections in cystic fibrosis patients. In a study published online today in Genome Research (www.genome.org), researchers have used genomic techniques to study a particularly virulent strain of P. aeruginosa, uncovering genetic clues to its success that will aid in the design of novel therapeutic strategies.

Stored Embryos, a Problem for Their Parents

Once fertility treatments are completed, many embryos remain frozen, a byproduct of women's treatment options, which include the possibility of preserving eggs if regular therapies fail. The logic behind this is for patients to be able to have children, even if through in-vitro fertilization. But most women have no plans for their embryos once their treatment is complete.

'Nanotechnology' Building Big Future for Consumer Goods

With rising application of nanotechnology in consumer goods and medical treatments, the global nanotechnology industry will see fast-paced growth in near future.

Hybrigenics receives first patent grant on chemical inhibitors of Ubiquitin-Specific Proteases

Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new cancer treatments and specialized in protein interactions, announced it has been granted the first in a series of patent applications covering the company's proprietary chemical inhibitors of Ubiquitin-Specific Proteases (USPs).

Hybrigenics Receives First Patent Grant on Chemical Inhibitors of Ubiquitin-Specific Proteases

Paris, December 11th, 2008 - Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new cancer treatments and specialized in protein interactions, announced today it has been granted the first in a series of patent applications covering the company's proprietary chemical inhibitors of Ubiquitin-Specific Proteases (USPs).

Scientists link gene to hypertension

US researchers have discovered a variant of a common gene linked to high blood pressure possibly paving the way towards better treatments of the illness, a new study released on Monday says.

Scientists link gene to hypertension

US researchers have discovered a variant of a common gene linked to high blood pressure possibly paving the way towards better treatments of the illness, a new study released on Monday says.

Scientists link gene to hypertension

US researchers have discovered a variant of a common gene linked to high blood pressure possibly paving the way towards better treatments of the illness, a new study released on Monday says.

High blood pressure genetic link discovered

US researchers have discovered a variant of a common gene linked to high blood pressure possibly paving the way towards better treatments of the illness, a new study released on Monday says.

High-blood pressure genetic link discovered

WASHINGTON -- U.S. researchers have discovered a variant of a common gene linked to high-blood pressure, paving the way towards possible better treatments of the illness, a study said Monday. The gene, known as STK39, produces a protein which plays a role in helping the kidneys regulate the amount of salt inside a person's body.

First 'placebo gene' discovered

FOR the first time, a gene is being linked to increased susceptibility to the placebo effect, the mysterious capacity some people have to benefit from sham treatments.

Neurocosmetics and Vectorization Big in 2009

Science and technology will play a big part in 2009 personal care ingredients, according to a post by beauty blog Beauty Editor Post. The blog maintains to be a consumer's guide to spa treatments, professional skin care and antiaging product reviews written by skin care educators and industry veterans.

Fed. Circ. Issues Mixed Ruling In Apnea Patent Case

Law360, New York (December 16, 2008) -- An appeals court has affirmed in part and reversed in part a judge's ruling in a patent dispute between Invacare Inc. and Respironics Inc., two companies that make treatments for sleep apnea.

People in the US and the UK show strong similarities in their attitudes toward nanotechnologies

The results of a new U.S.-U.K. study published in this week's journal Nature Nanotechnology show that ordinary people in both countries hold very positive views of nanotechnologies and what the future of these technologies might bring. Participants in both countries indicated a significantly higher comfort level with energy applications of nanotechnologies than with applications used in health treatments.

US and UK people's similarities in their attitudes toward nanotechnologies

The results of a new U.S.–U.K. study published in this week's journal Nature Nanotechnology show that ordinary people in both countries hold very positive views of nanotechnologies and what the future of these technologies might bring. Participants in both countries indicated a significantly higher comfort level with energy applications of nanotechnologies than with applications used in health treatments.

Search took 0.02 seconds.